Vera Therapeutics Q1 net loss $51.7M; on track for Phase 3 atacicept results in 2Q 2025

Vera Therapeutics, Inc.

2025-Q1 EPS reported -$0.81

Net loss of $51.7M ($0.81/share) vs $28.4M ($0.56/share) same quarter last year.
Cash, equivalents and marketable securities of $589.8M as of March 31, 2025.
Primary endpoint results from atacicept pivotal Phase 3 ORIGIN trial in IgAN expected in 2Q 2025.
BLA submission for atacicept accelerated approval planned for 4Q 2025; potential launch in 2026.
Expanded atacicept program into primary membranous nephropathy, FSGS, and minimal change disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.